(Q38002469)

26 August 2017

title

New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies (English)

1 reference

ubiquitin-proteasome system

26 August 2017

main subject

0 references

author name string

Enrique Grande

1

1 reference

26 August 2017

Julie Earl

2

1 reference

26 August 2017

Raquel Fuentes

3

1 reference

26 August 2017

Alfredo Carrato

4

1 reference

26 August 2017

publication date

1 April 2012

1 reference

Expert Review of Anticancer Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

457-467

1 reference

26 August 2017

cites work

Global cancer statistics

1 reference

Ubiquitin and ubiquitin-like proteins in cancer pathogenesis

21 January 2018

1 reference

Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets

21 January 2018

1 reference

The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation

21 January 2018

1 reference

Degradation of ubiquitin: the fate of the cellular reaper

21 January 2018

1 reference

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives

21 January 2018

1 reference

Recognition and processing of ubiquitin-protein conjugates by the proteasome

21 January 2018

1 reference

Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction

21 January 2018

1 reference

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex

21 January 2018

1 reference

Modification of proteins by ubiquitin and ubiquitin-like proteins

21 January 2018

1 reference

Deubiquitylating enzymes and disease

21 January 2018

1 reference

Concepts in sumoylation: a decade on

21 January 2018

1 reference

A genomic and functional inventory of deubiquitinating enzymes

21 January 2018

1 reference

Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.

21 January 2018

1 reference

The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe?

21 January 2018

1 reference

The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy

21 January 2018

1 reference

Autophagosome formation: core machinery and adaptations

21 January 2018

1 reference

Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection

21 January 2018

1 reference

SUMO in cancer--wrestlers wanted

21 January 2018

1 reference

The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. 'Protein modifications: beyond the usual suspects' review series

21 January 2018

1 reference

ISG15 as a novel tumor biomarker for drug sensitivity.

21 January 2018

1 reference

Targeting the ubiquitin system in cancer therapy

21 January 2018

1 reference

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

IAPs, RINGs and ubiquitylation

21 January 2018

1 reference

Regulating the p53 system through ubiquitination

21 January 2018

1 reference

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

21 January 2018

1 reference

The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis

21 January 2018

1 reference

The p53--Mdm2--HAUSP complex is involved in p53 stabilization by HAUSP.

21 January 2018

1 reference

Inactivation of HAUSP in vivo modulates p53 function

21 January 2018

1 reference

Inactivation of the p53 pathway in retinoblastoma.

21 January 2018

1 reference

A dynamic role of HAUSP in the p53-Mdm2 pathway

21 January 2018

1 reference

Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

21 January 2018

1 reference

Targeting the ubiquitin-proteasome system for cancer therapy

21 January 2018

1 reference

The VHL tumor suppressor and HIF: insights from genetic studies in mice

21 January 2018

1 reference

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

21 January 2018

1 reference

The ubiquitin-specific protease USP34 regulates axin stability and Wnt/β-catenin signaling

21 January 2018

1 reference

Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.

21 January 2018

1 reference

Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2

21 January 2018

1 reference

Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway

21 January 2018

1 reference

Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells.

21 January 2018

1 reference

Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells.

21 January 2018

1 reference

TRIM proteins and cancer.

21 January 2018

1 reference

Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC protein

21 January 2018

1 reference

The cellular level of TRIM31, an RBCC protein overexpressed in gastric cancer, is regulated by multiple mechanisms including the ubiquitin-proteasome system

21 January 2018

1 reference

21 January 2018

1 reference

The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer

21 January 2018

1 reference

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells

21 January 2018

1 reference

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53

21 January 2018

1 reference

Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fisher 344 male rats [Mechanisms of Ageing and Development 123 (2002) 1665-1680].

21 January 2018

1 reference

Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome

21 January 2018

1 reference

The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc

21 January 2018

1 reference

Parkin and relatives: the RBR family of ubiquitin ligases

21 January 2018

1 reference

Parkin gene alterations in hepatocellular carcinoma

21 January 2018

1 reference

Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers

21 January 2018

1 reference

NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma

21 January 2018

1 reference

Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma

21 January 2018

1 reference

Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers

21 January 2018

1 reference

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

21 January 2018

1 reference

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer

21 January 2018

1 reference

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study

21 January 2018

1 reference

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

21 January 2018

1 reference

Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

21 January 2018

1 reference

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

21 January 2018

1 reference

Observation of a Centrality-Dependent Dijet Asymmetry in Lead-Lead Collisions atsNN=2.76 TeVwith the ATLAS Detector at the LHC

21 January 2018

1 reference

The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias

21 January 2018

1 reference

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

21 January 2018

1 reference

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

21 January 2018

1 reference

Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover

21 January 2018

1 reference

Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor

21 January 2018

1 reference

Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening

21 January 2018

1 reference

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

21 January 2018

1 reference

Carfilzomib: a novel second-generation proteasome inhibitor

21 January 2018

1 reference

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

Discovery and development of the anticancer agent salinosporamide A (NPI-0052).

21 January 2018

1 reference

Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs

21 January 2018

1 reference

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

21 January 2018

1 reference

Molecular mechanisms and proposed targets for selected anticancer gold compounds

21 January 2018

1 reference

21 January 2018

1 reference

DNA damage: ubiquitin marks the spot

21 January 2018

1 reference

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.12.26

1 reference

26 August 2017

1 reference